

Shari S Rogal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1525374/publications.pdf>

Version: 2024-02-01

69
papers

1,751
citations

236925

25
h-index

302126

39
g-index

71
all docs

71
docs citations

71
times ranked

2164
citing authors

#	ARTICLE	IF	CITATIONS
1	AASLD Practice Guidance: Palliative care and symptom-based management in decompensated cirrhosis. <i>Hepatology</i> , 2022, 76, 819-853.	7.3	56
2	Core implementation strategies for improving cirrhosis care in the Veterans Health Administration. <i>Hepatology</i> , 2022, 76, 404-417.	7.3	11
3	Using Intervention Mapping to Develop a Novel Pain Self-Management Intervention for People with Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 5063-5078.	2.3	2
4	Patient- and provider-level factors that underlie alcohol use disorder treatment offer and acceptance in veterans with cirrhosis. <i>Alcoholism: Clinical and Experimental Research</i> , 2022, 46, 809-814.	2.4	5
5	Area Deprivation Index and Gut-Brain Axis in Cirrhosis. <i>Clinical and Translational Gastroenterology</i> , 2022, 13, e00495.	2.5	2
6	Assessment of Alcohol and Other Substance Use in Patients With Chronic Liver Disease. <i>Clinical Liver Disease</i> , 2022, 20, 61-65.	2.1	1
7	Getting To Implementation (GTI)-Teach: A seven-step approach for teaching the fundamentals of implementation science. <i>Journal of Clinical and Translational Science</i> , 2022, 6, .	0.6	1
8	Source of Post-Transplant Care and Mortality among Kidney Transplant Recipients Dually Enrolled in VA and Medicare. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 437-445.	4.5	9
9	Spontaneous Bacterial Peritonitis. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1118.	7.4	6
10	Medication Treatment of Active Opioid Use Disorder in Veterans With Cirrhosis. <i>American Journal of Gastroenterology</i> , 2021, 116, 1406-1413.	0.4	2
11	The Hepatic Innovation Team Collaborative: A Successful Population-Based Approach to Hepatocellular Carcinoma Surveillance. <i>Cancers</i> , 2021, 13, 2251.	3.7	12
12	Strategies to Improve Delivery of Cirrhosis Care. <i>Current Treatment Options in Gastroenterology</i> , 2021, 19, 369-379.	0.8	3
13	HCV Elimination in the US Department of Veterans Affairs. <i>Clinical Liver Disease</i> , 2021, 18, 1-6.	2.1	8
14	Patient perceptions of successful hepatitis C virus treatment adherence in Veterans. <i>GastroHep</i> , 2021, 3, 307-325.	0.6	0
15	Development and Implementation of Multidisciplinary Liver Tumor Boards in the Veterans Affairs Health Care System: A 10-Year Experience. <i>Cancers</i> , 2021, 13, 4849.	3.7	4
16	Mapping the road to elimination: a 5-year evaluation of implementation strategies associated with hepatitis C treatment in the veterans health administration. <i>BMC Health Services Research</i> , 2021, 21, 1348.	2.2	12
17	Characteristics of opioid prescribing to outpatients with chronic liver diseases: A call for action. <i>PLoS ONE</i> , 2021, 16, e0261377.	2.5	2
18	Provider Perceptions of Hepatitis C Treatment Adherence and Initiation. <i>Digestive Diseases and Sciences</i> , 2020, 65, 1324-1333.	2.3	15

#	ARTICLE	IF	CITATIONS
19	Impact of Alcohol Use Disorder Treatment on Clinical Outcomes Among Patients With Cirrhosis. <i>Hepatology</i> , 2020, 71, 2080-2092.	7.3	106
20	Characterizing patient-reported outcomes in veterans with cirrhosis. <i>PLoS ONE</i> , 2020, 15, e0238712.	2.5	3
21	Opioid Avoidance After Liver Transplantation: The Ever-Shifting Pain Management Paradigm. <i>Liver Transplantation</i> , 2020, 26, 1221-1223.	2.4	1
22	Getting to implementation: a protocol for a Hybrid III stepped wedge cluster randomized evaluation of using data-driven implementation strategies to improve cirrhosis care for Veterans. <i>Implementation Science</i> , 2020, 15, 92.	6.9	14
23	Physical Function, Physical Activity, and Quality of Life After Liver Transplantation. <i>Liver Transplantation</i> , 2020, 26, 702-708.	2.4	53
24	Tracking implementation strategies in the randomized rollout of a Veterans Affairs national opioid risk management initiative. <i>Implementation Science</i> , 2020, 15, 48.	6.9	16
25	In inpatients with cirrhosis opioid use is common and associated with length of stay and persistent use post-discharge. <i>PLoS ONE</i> , 2020, 15, e0229497.	2.5	10
26	Prescription opioid use is common and associated with worse clinical outcomes in individuals with chronic liver disease. <i>GastroHep</i> , 2020, 2, 13-21.	0.6	0
27	Opioid prescriptions are associated with hepatic encephalopathy in a national cohort of patients with compensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 652-660.	3.7	30
28	Medical cannabis use among individuals with cancer: An unresolved and timely issue. <i>Cancer</i> , 2020, 126, 1832-1836.	4.1	10
29	Strategy Configurations Directly Linked to Higher Hepatitis C Virus Treatment Starts. <i>Medical Care</i> , 2020, 58, e31-e38.	2.4	54
30	Letter: are opioid prescriptions associated with hepatic encephalopathy in patients with compensated cirrhosis? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 743-744.	3.7	0
31	Moving Toward Impact: An Introduction to Implementation Science for Gastroenterologists and Hepatologists. <i>Gastroenterology</i> , 2020, 159, 2007-2012.	1.3	4
32	Access to Comprehensive Services for Advanced Liver Disease in the Veterans Health Administration. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3471-3479.	2.3	7
33	Protocol for evaluating the nationwide implementation of the VA Stratification Tool for Opioid Risk Management (STORM). <i>Implementation Science</i> , 2019, 14, 5.	6.9	18
34	Characteristics of Opioid Prescriptions to Veterans With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1165-1174.e3.	4.4	25
35	Longitudinal assessment of the association between implementation strategy use and the uptake of hepatitis C treatment: Year 2. <i>Implementation Science</i> , 2019, 14, 36.	6.9	25
36	Determinants of Hepatitis C Treatment Adherence and Treatment Completion Among Veterans in the Direct Acting Antiviral Era. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3001-3012.	2.3	8

#	ARTICLE	IF	CITATIONS
37	The Assessment and Management of Pain in Cirrhosis. <i>Current Hepatology Reports</i> , 2018, 17, 42-51.	0.9	27
38	Post-transplant Outcomes of Persons Receiving a Liver Graft for Alcoholic Liver Disease. <i>Alcohol and Alcoholism</i> , 2018, 53, 157-165.	1.6	20
39	Screening and Treating Hepatitis C in the VA: Achieving Excellence Using Lean and System Redesign. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2018, 35, 24-29.	0.6	11
40	Integrating Care for Patients With Chronic Liver Disease and Mental Health and Substance Use Disorders. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2018, 35, S14-S23.	0.6	10
41	Primary Care and Hepatology Providerâ€™ Perceived Barriers to and Facilitators of Hepatitis C Treatment Candidacy and Adherence. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1933-1943.	2.3	50
42	Liver Transplantation in the Obese Cirrhotic Patient. <i>Transplantation</i> , 2017, 101, 2288-2296.	1.0	67
43	High-dose opioid use and liver transplantation: An underestimated problem?. <i>Liver Transplantation</i> , 2017, 23, 285-287.	2.4	6
44	Opioid and opioid substitution therapy in liver transplant candidates: A survey of center policies and practices. <i>Clinical Transplantation</i> , 2017, 31, e13119.	1.6	25
45	The association between implementation strategy use and the uptake of hepatitis C treatment in a national sample. <i>Implementation Science</i> , 2017, 12, 60.	6.9	60
46	Risk factors for hospitalizations among patients with cirrhosis: A prospective cohort study. <i>PLoS ONE</i> , 2017, 12, e0187176.	2.5	7
47	The Patient-Provider Relationship Is Associated with Hepatitis C Treatment Eligibility: A Prospective Mixed-Methods Cohort Study. <i>PLoS ONE</i> , 2016, 11, e0148596.	2.5	15
48	Cost-effectiveness of new antiviral regimens for treatment of U.S. veterans with hepatitis C. <i>Hepatology</i> , 2016, 63, 428-436.	7.3	33
49	Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients. <i>Value in Health</i> , 2016, 19, 326-334.	0.3	30
50	Association between opioid use and readmission following liver transplantation. <i>Clinical Transplantation</i> , 2016, 30, 1222-1229.	1.6	22
51	Incidence and Progression of Chronic Kidney Disease After Hepatitis C Seroconversion: Results from ERCHIVES. <i>Digestive Diseases and Sciences</i> , 2016, 61, 930-936.	2.3	39
52	Pre-Transplant Depression Is Associated with Length of Hospitalization, Discharge Disposition, and Survival after Liver Transplantation. <i>PLoS ONE</i> , 2016, 11, e0165517.	2.5	29
53	Fibromyalgia Symptoms and Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1482-1489.	2.3	22
54	Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES. <i>Hepatology</i> , 2015, 62, 365-374.	7.3	91

#	ARTICLE	IF	CITATIONS
55	Inflammation, Psychiatric Symptoms, and Opioid Use Are Associated With Pain and Disability in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1009-1016.	4.4	46
56	Rapid improvement in post-infectious gastroparesis symptoms with mirtazapine. <i>World Journal of Gastroenterology</i> , 2014, 20, 6671.	3.3	21
57	Novel therapy for non-cirrhotic hyperammonemia due to a spontaneous splenorenal shunt. <i>World Journal of Gastroenterology</i> , 2014, 20, 8288.	3.3	17
58	Relationship Between Detection of Adenomas by Flexible Sigmoidoscopy and Interval Distal Colorectal Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 73-78.	4.4	38
59	Pain and Opioid Use in Chronic Liver Disease. <i>Digestive Diseases and Sciences</i> , 2013, 58, 2976-2985.	2.3	54
60	Early Treatment of Depressive Symptoms and Long-Term Survival After Liver Transplantation. <i>American Journal of Transplantation</i> , 2013, 13, 928-935.	4.7	72
61	Healthcare utilization in chronic liver disease: the importance of pain and prescription opioid use. <i>Liver International</i> , 2013, 33, 1497-1503.	3.9	35
62	Hepatic steatosis in diabetic patients does not predict adverse liver-related or cardiovascular outcomes. <i>Liver International</i> , 2013, 33, 1575-1582.	3.9	21
63	Risk Factors for Frequent Readmissions and Barriers to Transplantation in Patients with Cirrhosis. <i>PLoS ONE</i> , 2013, 8, e55140.	2.5	37
64	Pretransplant depression, antidepressant use, and outcomes of orthotopic liver transplantation. <i>Liver Transplantation</i> , 2011, 17, 251-260.	2.4	63
65	Gallbladder Agenesis. <i>Case Reports in Gastroenterology</i> , 2011, 5, 654-662.	0.6	41
66	A Sweet Source of Abdominal Pain. <i>New England Journal of Medicine</i> , 2011, 364, 1762-1767.	27.0	16
67	A Sweet Source of Abdominal Pain. <i>New England Journal of Medicine</i> , 2011, 364, e30.	27.0	1
68	Effects of posttraumatic stress disorder on pregnancy outcomes. <i>Journal of Affective Disorders</i> , 2007, 102, 137-143.	4.1	109
69	Treatment practices for childhood posttraumatic stress disorder. <i>Child Abuse and Neglect</i> , 2001, 25, 123-135.	2.6	81